-
Product Insights
New![]()
Net Present Value Model: GlycoMimetics Inc’s Uproleselan sodium
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Sangamo Therapeutics Inc’s Isaralgagene Civaparvovec
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GMI-1687 in Sickle Cell Disease With Vaso-Occlusive Crisis Drug Details: GMI-1687 is under development for...
-
Sector Analysis
![]()
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Company Profile
![]()
GlycoMimetics Inc – Company Profile
GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. The company uses proprietary glycobiology technology to develop treatments for diseases. It...
Add to Basket -
Product Insights
![]()
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
![]()
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
![]()
Net Present Value Model: Uproleselan sodium
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Uproleselan sodium Drug Details Uproleselan sodium...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – uproleselan sodium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry uproleselan sodium Drug Details Uproleselan sodium (GMI-1271) is under the development for the treatment...
-
Product Insights
![]()
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.